Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2

Joseph Newman, Nazia Thakur, Thomas P. Peacock, Dagmara Bialy, Ahmed ME Elreafey, Carlijn Bogaardt, Daniel L. Horton, Sammy Ho, Thivya Kankeyan, Christine Carr, Katja Hoschler, Wendy S. Barclay, Gayatri Amirthalingam, Kevin Brown, Bryan Charleston, Dalan Bailey
doi: https://doi.org/10.1101/2021.12.23.21268293
Joseph Newman
1The Pirbright Institute, Guildford, Surrey, GU24 0NF, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nazia Thakur
1The Pirbright Institute, Guildford, Surrey, GU24 0NF, United Kingdom
2Nuffield Department of Medicine, The Jenner Institute, Oxford, OX3 7DQ, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas P. Peacock
3Department of Infectious Disease, Imperial College – London, W2 1PG, United Kingdom
4UK Health Security Agency (UKHSA), UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dagmara Bialy
1The Pirbright Institute, Guildford, Surrey, GU24 0NF, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmed ME Elreafey
1The Pirbright Institute, Guildford, Surrey, GU24 0NF, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlijn Bogaardt
5Department of Pathology and Infectious Diseases, School of Veterinary Medicine, University of Surrey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel L. Horton
5Department of Pathology and Infectious Diseases, School of Veterinary Medicine, University of Surrey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sammy Ho
4UK Health Security Agency (UKHSA), UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thivya Kankeyan
4UK Health Security Agency (UKHSA), UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Carr
4UK Health Security Agency (UKHSA), UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katja Hoschler
4UK Health Security Agency (UKHSA), UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy S. Barclay
3Department of Infectious Disease, Imperial College – London, W2 1PG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gayatri Amirthalingam
4UK Health Security Agency (UKHSA), UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Brown
4UK Health Security Agency (UKHSA), UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bryan Charleston
1The Pirbright Institute, Guildford, Surrey, GU24 0NF, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dalan Bailey
1The Pirbright Institute, Guildford, Surrey, GU24 0NF, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: dalan.bailey@pirbright.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

SARS-CoV-2 variants threaten the effectiveness of tools we have developed to mitigate against serious COVID-19. This is especially true in clinically vulnerable sections of society including the elderly. Using sera from BNT162b2 (Pfizer–BioNTech) vaccinated individuals aged between 70 and 89 (vaccinated with two doses 3-weeks apart) we examined the neutralising antibody (nAb) response to wildtype SARS-CoV-2. Between 3 and 20-weeks post 2nd dose, nAb titres dropped 4.9-fold to a median titre of 21.3 (ND80) with 21.6% of individuals having no detectable nAbs at the later time point. Experiments examining the neutralisation of twenty-one different SARS-CoV-2 variant spike proteins confirmed a significant potential for antigenic escape, especially for the Omicron (BA.1), Beta (B.1.351), Delta (B.1.617.2), Theta (P.3), C.1.2 and B.1.638 variants. Interestingly, however, the recently-emerged sub-lineage AY.4.2 was more efficiently neutralised than parental Delta pseudotypes. Combining pseudotype neutralisation with specific receptor binding domain (RBD) ELISAs we confirmed that changes to position 484 in the spike RBD were predominantly responsible for SARS-CoV-2 nAb escape, although the effect of spike mutations is both combinatorial and additive. Lastly, using sera from the same individuals boosted with a 3rd dose of BNT162b2 we showed that high overall levels of neutralising antibody titre can provide significant levels of cross-protection against Omicron. These data provide evidence that SARS-CoV-2 neutralising antibodies wane over time and that antigenically variable SARS-CoV-2 variants are circulating, highlighting the importance of ongoing surveillance and booster programmes. Furthermore, they provide important data to inform risk assessment of new SARS-CoV-2 variants, such as Omicron, as they emerge.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the MRC funded G2P-UK National Virology Consortium; G2P-UK; A National Virology Consortium to address phenotypic consequences of SARS-CoV-2 genomic variation (MR/W005611/1). JN, NT, DB, AE, BC and DB were also funded by The Pirbright Institute BBSRC institute strategic programme grant (BBS/E/I/COV07001, BBS/E/I/00007031, BBS/E/I/00007038, BBS/E/I/00007039 and BBS/E/I/00007034) with NT receiving studentship support from BB/T008784/1. CB and DH were supported by funding from the European Union Horizon 2020 Research and Innovation programme under grant agreement No 773830: One Health European Joint Programme.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

United Kingdom Health Security Agency Research Ethics Governance Group of United Kingdom Health Security Agency gave ethical approval for this work; reference NR0253; 18/01/21.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 24, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2
Joseph Newman, Nazia Thakur, Thomas P. Peacock, Dagmara Bialy, Ahmed ME Elreafey, Carlijn Bogaardt, Daniel L. Horton, Sammy Ho, Thivya Kankeyan, Christine Carr, Katja Hoschler, Wendy S. Barclay, Gayatri Amirthalingam, Kevin Brown, Bryan Charleston, Dalan Bailey
medRxiv 2021.12.23.21268293; doi: https://doi.org/10.1101/2021.12.23.21268293
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2
Joseph Newman, Nazia Thakur, Thomas P. Peacock, Dagmara Bialy, Ahmed ME Elreafey, Carlijn Bogaardt, Daniel L. Horton, Sammy Ho, Thivya Kankeyan, Christine Carr, Katja Hoschler, Wendy S. Barclay, Gayatri Amirthalingam, Kevin Brown, Bryan Charleston, Dalan Bailey
medRxiv 2021.12.23.21268293; doi: https://doi.org/10.1101/2021.12.23.21268293

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1238)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10020)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2452)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1642)
  • Health Policy (752)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (74)
  • Nephrology (268)
  • Neurology (2280)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (536)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (157)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (312)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4832)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (491)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)